0001860657
false
0001860657
2023-07-05
2023-07-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 5, 2023
ALLARITY THERAPEUTICS, INC.
(Exact name of registrant as specified in our charter)
Delaware |
|
001-41160 |
|
87-2147982 |
(State
or Other Jurisdiction
of Incorporation) |
|
(Commission File
Number) |
|
(IRS
Employer
Identification
No.) |
24 School Street, 2nd Floor,
Boston,
MA |
|
02108 |
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
(401)
426-4664
(Registrant’s
telephone number, including area code)
Not
applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common Stock, par value $0.0001 per share |
|
ALLR |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events.
On July
5, 2023, Allarity Therapeutics, Inc. (the “Company”) issued a press release regarding initial results of its European Phase
2 clinical trial evaluating IXEMPRA® in metastatic breast cancer (mBC) patients selected with the DRP® IXEMPRA® companion
diagnostic (CDx) candidate. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. and
is incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Allarity
Therapeutics, Inc. |
|
|
|
By: |
/s/
James G. Cullem |
|
|
James
G. Cullem
Chief
Executive Officer |
|
|
|
Dated:
July 5, 2023 |
|
|
2
Exhibit 99.1
Initial
Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for
Improved Clinical Benefit in DRP®-Selected
Metastatic Breast Cancer Patients
Boston,
MA (July 5, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (Nasdaq: ALLR), a clinical-stage
pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for
personalized cancer care, today announced initial results from its European Phase 2 clinical trial evaluating the efficacy of IXEMPRA®
in metastatic breast cancer (mBC) patients selected with the DRP®-IXEMPRA® companion diagnostic (CDx)
candidate. Researchers prescreened mBC patients using Allarity’s DRP®-IXEMPRA® CDx, a complex transcriptomic
signature comprising multiple mRNA biomarkers of drug response/resistance. Patients were assigned a DRP®-score, and those
with scores above 67% were selected for treatment with IXEMPRA®.
Of
the 36 patients screened with the DRP®-IXEMPRA® CDx, investigators identified five DRP®
positive patients. Among the evaluable patients assessed up to the data evaluation cut-off, there were promising signs of clinical benefit
in four out of four evaluable cases:
| ● | One
partial responder (PR) (tumor shrinkage of 66%). |
| ● | One
partial responder (PR) (tumor shrinkage of 59%). |
| ● | One
patient experienced 24 weeks of stable disease. |
| ● | One
patient experienced 19 weeks of stable disease. |
“We
are enthusiastic about these promising very early trial results since the observed clinical benefit rate exceeds what has been historically
observed for IXEMPRA® treatment without the DRP®-IXEMPRA® CDx patient selection. While
still early, these data suggest that the use of the DRP®-IXEMPRA® CDx for patient selection and treatment
may help identify mBC patients most able to benefit from this course of treatment. Accordingly, the DRP®-IXEMPRA®
CDx, if approved, may provide clinicians with an important diagnostic to guide patient treatment in this hard-to-treat population,”
said Marie Foegh, M.D., Chief Medical Officer of Allarity.
Allarity
Therapeutics, Inc. | 24 School Street, 2nd Floor | Boston, MA | U.S.A. | NASDAQ:
ALLR | www.allarity.com
The
study is in a very early stage of an ongoing open-label, single-arm trial, at multiple sites in Europe, evaluating the anti-tumor effect
of IXEMPRA® in patients with locally recurrent or metastatic breast cancer after previous chemotherapies, including a
taxane and an anthracycline. The included patients received a maximum of three prior lines of chemotherapies in the metastatic setting.
Allarity recently amended the clinical trial protocol, lowering the DRP® cut-off score in order to include more likely
responder patients while still excluding those unlikely to respond to the drug. The ultimate objective is to further refine the DRP®-IXEMPRA®
CDx criteria and broaden the enrollment of mBC patients who may substantially benefit from this treatment. The Company anticipates
an additional interim data readout before the end of this year.
The
DRP®-IXEMPRA® CDx is a transcriptomic signature comprising 191 mRNA biomarkers that are collectively predictive
of tumor sensitivity or resistance to IXEMPRA®. Using the DRP® CDx to select likely responder patients
while excluding likely resistant ones, Allarity aims to improve the benefit-risk ratio of IXEMPRA® in metastatic or locally
advanced breast cancer. The U.S. FDA-approved IXEMPRA® label currently indicates a monotherapy efficacy with an objective
response rate (ORR) of 12.4% and a clinical benefit rate (CBR) of 24.8% in metastatic or locally advanced breast cancer. However, the
initial data from the ongoing DRP®-guided Phase 2 study of IXEMPRA® suggest that the DRP®-IXEMPRA®
CDx may identify a subset of patients who potentially have an improved ORR and CBR as compared to monotherapy efficacy indicated
by the U.S. FDA-approved label for the drug. The DRP®-IXEMPRA® CDx is a clinical stage companion diagnostic
candidate and has not yet been approved by the U.S. FDA or the EMEA. Early trial results are insufficient to show statistical significance
and may not be a reliable indicator of subsequent trial results based on a larger patient population.
IXEMPRA®
was originally developed by Bristol Myers Squibb and is approved for metastatic breast cancer patients in the U.S., where it is
marketed by R-PHARM U.S., LLC. Allarity has the exclusive option rights for the development and commercialization of IXEMPRA®
in Europe.
Allarity’s
Chief Executive Officer, James G. Cullem, further stated, “We are encouraged by these promising, early clinical data suggesting
that mBC patients selected for treatment with IXEMPRA® using our DRP® companion diagnostic candidate for
the drug may have substantially improved clinical benefit versus unselected patients. Allarity looks forward to fully enrolling and completing
our ongoing Phase 2 trial for IXEMPRA®, and remains enthusiastic about advancing this program towards market approval
in Europe and, if approved, providing European mBC patients with first-time access to this beneficial drug.”
Allarity
Therapeutics, Inc. | 24 School Street, 2nd Floor | Boston, MA | U.S.A. | NASDAQ:
ALLR | www.allarity.com
About
Allarity Therapeutics
Allarity
Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated
companion diagnostic technology, the DRP® platform. The Company has a clinical-stage pipeline of three drug
candidates: stenoparib, a PARP inhibitor in Phase 2 development for ovarian cancer, and in Phase 1 development for advanced solid
tumors in a combination treatment with dovitinib, a pan-tyrosine kinase inhibitor (pan-TKI) that has previously been developed
through Phase 3 in renal cancer; and IXEMPRA® (Ixabepilone), a microtubule inhibitor approved in the U.S. and
marketed by R-PHARM U.S. for the treatment of second-line metastatic breast cancer, currently in Phase 2 development in Europe for
the same indication. Additionally, the Company has rights in two secondary assets: 2X-111, a liposomal formulation of doxorubicin
for metastatic breast cancer and/or glioblastoma multiforme (GBM), which is the subject of discussions for a restructured
out-license to Smerud Medical Research International AS; and LiPlaCis®, a liposomal formulation of cisplatin and its
accompanying DRP®, being developed via a partnership with CHOSA Oncology AB for late-stage metastatic breast cancer.
The Company is headquartered in the United States and maintains an R&D facility in Hoersholm, Denmark. For more information,
please visit the Company’s website at www.Allarity.com.
About
the Drug Response Predictor – DRP® Companion Diagnostic
Allarity
uses its drug-specific DRP® to select those patients who, by the genetic signature of their cancer, are found to
have a high likelihood of responding to the specific drug. By screening patients before treatment, and only treating those patients with
a sufficiently high DRP® score, the therapeutic response rate can be significantly increased. The DRP®
method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from
cell lines combined with clinical tumor biology filters and prior clinical trial outcomes. DRP® is based on messenger
RNA from patient biopsies. The DRP® platform has proven its ability to provide a statistically significant prediction
of the clinical outcome from drug treatment in cancer patients in 37 out of 47 clinical studies that were examined (both retrospective
and prospective), including ongoing, prospective Phase 2 trials of Stenoparib and IXEMPRA®. The DRP®
platform, which can be used in all cancer types and is patented for more than 70 anti-cancer drugs, has been extensively published in
peer-reviewed literature.
Follow
Allarity on Social Media
LinkedIn: https://www.linkedin.com/company/allaritytx/
Twitter: https://twitter.com/allaritytx
Allarity
Therapeutics, Inc. | 24 School Street, 2nd Floor | Boston, MA | U.S.A. | NASDAQ:
ALLR | www.allarity.com
Forward-Looking
Statements
This
press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements provide Allarity’s current expectations or forecasts of future events. The words “anticipates,”
“believe,” “continue,” “could,” “estimate,” “expect,” “intends,”
“may,” “might,” “plan,” “possible,” “potential,” “predicts,”
“project,” “should,” “would” and similar expressions may identify forward-looking statements, but
the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not
limited to, statements related to the expected availability of capital to fund its anticipated clinical trials, statements related to
advancing dovitinib in combination with stenoparib or another therapeutic candidate or other approved drug, any statements related to
ongoing clinical trials for stenoparib as a monotherapy or in combination with another therapeutic candidate for the treatment of advanced
ovarian cancer, or ongoing clinical trials (in Europe) for IXEMPRA® for the treatment of metastatic
breast cancer, statements relating to the effectiveness of the Company’s DRP® companion diagnostics
platform in predicting whether a particular patient is likely to respond to a specific drug, and statements related to the Company’s
ability to regain compliance with the Nasdaq Listing Rule. Any forward-looking statements in this press release are based on management’s
current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not
limited to, the risk that the Company is not able to raise sufficient capital to support its current and anticipated clinical trials, the
risk that results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially
change following more comprehensive reviews of the data, and as more patient data become available, the risk that results of a clinical
study are subject to interpretation and additional analyses may be needed and/or may contradict such results, the receipt of regulatory
approval for dovitinib or any of our other therapeutic candidates or, if approved, the successful commercialization of such products,
the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the
risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving our therapeutic
candidates, and the risk that the current COVID-19 pandemic will impact the Company’s current and future clinical trials and the
timing of the Company’s preclinical studies and other operations. For a discussion of other risks and uncertainties, and other
important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see
the section entitled “Risk Factors” in our Form 10-K annual report on file with the Securities and Exchange Commission,
available at the Securities and Exchange Commission’s website at www.sec.gov , and as well as discussions
of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the Securities and
Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update
this information unless required by law.
###
Company
Contact:
investorrelations@allarity.com
U.S.
Media Contact:
Mike Beyer
Sam Brown, Inc.
+1 (312) 961-2502
mikebeyer@sambrown.com
EU Media Contact:
Thomas Pedersen
Carrotize PR & Communications
+45 6062 9390
tsp@carrotize.com
Allarity
Therapeutics, Inc. | 24 School Street, 2nd Floor | Boston, MA | U.S.A. | NASDAQ:
ALLR | www.allarity.com
Page
4 of 4
v3.23.2
Cover
|
Jul. 05, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Jul. 05, 2023
|
Entity File Number |
001-41160
|
Entity Registrant Name |
ALLARITY THERAPEUTICS, INC.
|
Entity Central Index Key |
0001860657
|
Entity Tax Identification Number |
87-2147982
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
24 School Street
|
Entity Address, Address Line Two |
2nd Floor
|
Entity Address, City or Town |
Boston
|
Entity Address, State or Province |
MA
|
Entity Address, Postal Zip Code |
02108
|
City Area Code |
401
|
Local Phone Number |
426-4664
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value $0.0001 per share
|
Trading Symbol |
ALLR
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Allarity Therapeutics (NASDAQ:ALLR)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Allarity Therapeutics (NASDAQ:ALLR)
Historical Stock Chart
Von Jun 2023 bis Jun 2024